In vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004

Keizo Yamaguchi,Akira Ohno,Yoshikazu Ishii,Kazuhiro Tateda,Morihiro Iwata,Kouji Akizawa,Chikara Shimizu,Tasuku Hayashi,Mitsuo Kaku,Hiroyuki Kunishima,Miho Kitagawa,Makoto Miki,Chizuko Kawamura,Minoru Yasujima,Hiromi Tashiro,Hiroko Horiuchi,Yosei Katayama,Akira Suwabe,Makiko Kurota,Kenji Kikuchi,Satoru Kuroki,Katsu Hirayama,Toshiaki Takahashi,Takanori Gotou,Keita Morikane,Reiko Ota,Takuo Nakagawa,Kyoji Moriya,Mitsuru Murata,Akiko Yoneyama,Shigemi Kondou,Shigeki Misawa,Imao Sekine,Joji Shiotani,Tomohiro Nakayama,Michiko Yagoshi,Hajime Horiuchi,Yoko Tazawa,Kanno H,Masanori Aihara,Kenichiro Yamazaki,Hideyuki Okamoto,Kosuke Haruki,Junko Yazawa,Eiko Nagano,Motoi Okada,Yasuko Fukuda,Hiromi Ikari,Shigefumi Maesaki,Giichi Hashikita,Midori Sumitomo,Eiji Miyajima,Takefumi Saito,Nobuyuki Taniguchi,Akira Hishinuma,Yoshitaka Yamamoto,Yuki Okamoto,Nobuo Yamane,Ryou Maruyama,Chieko Kawashima,Masami Murakami,Sachie Yomoda,Tetsuo Machida,Yukio Ozaki,Takashi Uchida,Hisashi Baba,Yasuyuki Sugiura,Konomi Kondo,Takako Yamada,Hideo Gonda,Ikuo Yamaguchi,Toshiyuki Akahori,Keiichi Uemura,Masato Maekawa,Hitoshi Yoshimura,Kaname Nakatani,Yoshiko Matsushima,Tsutomu Nobori,Yoshinori Fujimoto,Asano Y,Asami Morinaga,Shinichi Fujita,Yasuko Senda,Yukio Hida,Masanori Yamashita,Haruyoshi Yoshida,Satoshi Ichiyama,Hidetoshi Okabe,Masayo Shigeta,Kaoru Shimizu,Hiroya Masaki,Hitoshi Heijyou,Hideo Nakaya,Takayuki Takubo,Tadashi Kusakabe,Tomonori Higashiyama,Hiroko Yoshida,Hiroshi Morishita,Shuji Matsuo,Hisashi Kono,Saori Fukuda,Reiko Sano,Yosuke Yuzuki,Norio Ikeda,Masaya Idomuki,Go Yamamoto,Syohiro Kinoshita,Seiji Kawano,Masao Doi,Yaeko Watanabe,Satomi Shimizu,Mikio Oka,Yoshihiro Kobashi,Nobuchika Kusano,Hiromitsu Fujiwara,Hiromi Murota,Shota Morishita,Atsushi Nagai,Hidehiko Moriyama,Yuki Taniguchi,Kiyoshi Negayama,Koji Murao,Hitoshi Miyamoto,Tetsuro Sugiura,Tamae Morita,Hiromi Tou,Akira Matsunaga,Dongchon Kang,Makiko Kiyosuke,Koichi Mashiba,Katsunori Yanagihara,Junichi Matsuda,Shigeru Kohno,Yosuke Aoki,Zenzo Nagasawa,Koji Kusaba,Kazufumi Hiramatsu,Tetsunori Saikawa,Hiroaki Miyanohara,Yuji Saeki,Ichiro Takajo,Akihiko Okayama,Nobuhisa Yamane,Isamu Nakasone

In vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004

2006

Abstract Awajanoran ( 1 ), a new dihydrobenzofuranderivative, was isolated from an agar-culture of Acremoniumsp. AWA16-1, which had been isolated fromsea mud collected at Awajishima Island in Japan. Thestructure of 1 was elucidated on the basis of a spectroscopicanalysis. This compound inhibited the growth of A549cells, the human lungadenocarcinoma cell line, with anIC 50 value of 17mg/ml, and also showed antimicrobialactivity. Keywords Awajanoran, Acremoniumsp. AWA16-1,dihydrobenzofuran, cytotoxic, antimicrobialMarine microorganisms have been drawing increasingattention as an important source of chemically interestingand biologically active secondary metabolites for thedevelopment of new pharmaceutical agents [1]. We havebeen screening marine-derived microorganism for theirantimicroalgal, antibacterial and antitumor activities to ﬁndnovel bioactive substances[2 4]. In the course ofscreening for antitumor substances, we detected activity inan extract of the marine-derived fungus, AWA16-1, whichhad been isolated from sea mud of Awajishima Island inJapan. This fungus (AWA16-1) was identiﬁed as

Keywords:

Correction
Source
Cite
Save

References

Citations